Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 52

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Sexually transmitted disease

Recruiting

A study to compare weekly or event-based use of doxycycline to prevent sexually transmitted infections in men who have sex with men and transgender women using HIV prevention medication.

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Doxycycline

Diabetic retinal oedema

Recruiting

A study to compare the efficacy and safety of AVT29 and aflibercept in patients with diabetic macular edema

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept

Hormone-refractory prostate cancer+1

Recruiting

A study evaluating the efficacy and safety of inavolisib and enzalutamide in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone

Systemic scleroderma+4

Recruiting

A long-term safety study of KYV-101 in patients previously treated for lupus nephritis, systemic sclerosis, myasthenia gravis, rheumatoid arthritis, or stiff person syndrome

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Kyv-101

Peripheral arterial occlusive disease+5

Recruiting

A study comparing one month versus one year of aspirin and clopidogrel treatment in patients with chronic limb-threatening ischemia after below-the-knee vascular therapy.

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Clopidogrel

Chronic kidney disease

Recruiting

Study of the effect of empagliflozin on protein levels in the urine for patients with type 2 diabetes and kidney disease.

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin

Hormone-refractory prostate cancer

Recruiting

Study of AMO959, lutetium (177Lu) vipivotide tetraxetan, and a drug combination for adults with advanced prostate cancer.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone

Herpes zoster

Recruiting

Evaluating the effect of recombinant varicella zoster virus glycoprotein E vaccine on heart problems and dementia in adults aged 65 years or older with herpes zoster

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years · Healthy volunteers
  • Substances:Recombinant Varicella Zoster Virus Glycoprotein E

Monogenic diabetes

Recruiting

Increasing the dose of glimepiride for patients with HNF1A-MODY or HNF4A-MODY diabetes

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Glimepiride

Chronic kidney disease+1

Recruiting

Effect of levothyroxine on kidney function in patients at risk of hypothyroidism after partial thyroid surgery

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Levothyroxine

Hepato-lenticular degeneration

Recruiting

A study comparing different zinc doses for the treatment of Wilson disease in healthy participants.

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Copper (64Cu) Chloride

Pyelonephritis

Recruiting

Comparing the effectiveness of 7 days versus 14 days of ciprofloxacin or ceftriaxone for treating kidney infection in kidney transplant recipients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ceftriaxone

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.